Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled phase 3 trial of DP-b99 in acute ischemic stroke
2009-012025-11Phase 3Terminated
- Sponsor
- D-Pharm
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing DP-b99 with Placebo (2 arms). Primary endpoint: Functional outcome by modified Rankin Scale at 90 days. Started Nov 2009; status: terminated.
02
Drugs
DP-b99
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2009-012025-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012025-11.